|
Clinical Trials and Observations
Citations 401-410 of 2742 total displayed.
|
Past content
(since May 1998):
|
A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group
- Deborah French, Leo H. Hamilton, Leonard A. Mattano, Jr, Harland N. Sather, Meenakshi Devidas, James B. Nachman, and Mary V. Relling
Blood 2008; 111: 4496-4499.
[Abstract]
[Full text]
[PDF]
Thalidomide for treatment of multiple myeloma: 10 years later
- Antonio Palumbo, Thierry Facon, Pieter Sonneveld, Joan Bladè, Massimo Offidani, Francesca Gay, Philippe Moreau, Anders Waage, Andrew Spencer, Heinz Ludwig, Mario Boccadoro, and Jean-Luc Harousseau
Blood 2008; 111: 3968-3977.
[Abstract]
[Full text]
[PDF]
Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphoma
- Mark Bower, Justin Stebbing, Mark Tuthill, Victoria Campbell, Johnathan Krell, Paul Holmes, Andrew Ozzard, Mark Nelson, Brian Gazzard, and Tom Powles
Blood 2008; 111: 3986-3990.
[Abstract]
[Full text]
[PDF]
Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia
- Kenneth I. Ataga, Wally R. Smith, Laura M. De Castro, Paul Swerdlow, Yogen Saunthararajah, Oswaldo Castro, Elliot Vichinsky, Abdullah Kutlar, Eugene P. Orringer, Greg C. Rigdon, and Jonathan W. Stocker, for the ICA-17043-05 Investigators
Blood 2008; 111: 3991-3997.
[Abstract]
[Full text]
[PDF]
Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach
- Alberto Tosetto, Giancarlo Castaman, and Francesco Rodeghiero
Blood 2008; 111: 3998-4003.
[Abstract]
[Full text]
[PDF]
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage
- Marco Ladetto, Federica De Marco, Fabio Benedetti, Umberto Vitolo, Caterina Patti, Alessandro Rambaldi, Alessandro Pulsoni, Maurizio Musso, Anna M. Liberati, Attilio Olivieri, Andrea Gallamini, Enrico Pogliani, Delia Rota Scalabrini, Vincenzo Callea, Francesco Di Raimondo, Vincenzo Pavone, Alessandra Tucci, Sergio Cortelazzo, Alessandro Levis, Mario Boccadoro, Ignazio Majolino, Alessandro Pileri, Alessandro M. Gianni, Roberto Passera, Paolo Corradini, and Corrado Tarella, for Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Intergruppo Italiano Linfomi (IIL)
Blood 2008; 111: 4004-4013.
[Abstract]
[Full text]
[PDF]
Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study
- Elizabeth C. Bluhm, Cécile Ronckers, Robert J. Hayashi, Joseph P. Neglia, Ann C. Mertens, Marilyn Stovall, Anna T. Meadows, Pauline A. Mitby, John A. Whitton, Sue Hammond, Joseph D. Barker, Sarah S. Donaldson, Leslie L. Robison, and Peter D. Inskip
Blood 2008; 111: 4014-4021.
[Abstract]
[Full text]
[PDF]
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
- Richard A. Larson, Brian J. Druker, Francois Guilhot, Stephen G. O'Brien, Gilles J. Riviere, Tillmann Krahnke, Insa Gathmann, and Yanfeng Wang, for the IRIS (International Randomized Interferon vs STI571) Study Group
Blood 2008; 111: 4022-4028.
[Abstract]
[Full text]
[PDF]
Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium
- Karin Ekström Smedby, Claire M. Vajdic, Michael Falster, Eric A. Engels, Otoniel Martínez-Maza, Jennifer Turner, Henrik Hjalgrim, Paolo Vineis, Adele Seniori Costantini, Paige M. Bracci, Elizabeth A. Holly, Eleanor Willett, John J. Spinelli, Carlo La Vecchia, Tongzhang Zheng, Nikolaus Becker, Silvia De Sanjosé, Brian C.-H. Chiu, Luigino Dal Maso, Pierluigi Cocco, Marc Maynadié, Lenka Foretova, Anthony Staines, Paul Brennan, Scott Davis, Richard Severson, James R. Cerhan, Elizabeth C. Breen, Brenda Birmann, Andrew E. Grulich, and Wendy Cozen
Blood 2008; 111: 4029-4038.
[Abstract]
[Full text]
[PDF]
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group
- Heinz Ludwig, Brian G. M. Durie, Vanessa Bolejack, Ingemar Turesson, Robert A. Kyle, Joan Blade, Rafael Fonseca, Meletios Dimopoulos, Kazuyuki Shimizu, Jesus San Miguel, Jan Westin, Jean-Luc Harousseau, Meral Beksac, Mario Boccadoro, Antonio Palumbo, Bart Barlogie, Chaim Shustik, Michele Cavo, Philip R. Greipp, Douglas Joshua, Michel Attal, Pieter Sonneveld, and John Crowley
Blood 2008; 111: 4039-4047.
[Abstract]
[Full text]
[PDF]
|
|
